Lineage Cell Therapeutics, Inc. (LCTX) SEC filings

LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3048% above fair value

$0.91−0.08 (-7.64%)

Close on Nov 13, 2026Market cap $231.31MP/E –Yield –

SEC filings

40 of Lineage Cell Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Nov 12, 2026	Nov 12, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jun 9, 2026	Jun 12, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 12, 2026	SEC EDGAR
Current report	8-K	May 12, 2026	May 12, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 29, 2026	Apr 29, 2026	SEC EDGAR
Current report	8-K	Mar 11, 2026	Mar 11, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 5, 2026	SEC EDGAR
Current report	8-K	Mar 5, 2026	Mar 5, 2026	SEC EDGAR
Current report	8-K	Nov 28, 2025	Nov 28, 2025	SEC EDGAR
Current report	8-K	Nov 20, 2025	Nov 24, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2025	Nov 12, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Aug 26, 2025	Aug 26, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 12, 2025	SEC EDGAR
Current report	8-K	Aug 12, 2025	Aug 12, 2025	SEC EDGAR
Current report	8-K	Jun 26, 2025	Jul 2, 2025	SEC EDGAR
Current report	8-K	Jun 23, 2025	Jun 23, 2025	SEC EDGAR
Current report	8-K	Jun 3, 2025	Jun 9, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 13, 2025	SEC EDGAR
Current report	8-K	May 13, 2025	May 13, 2025	SEC EDGAR
Current report	8-K	May 1, 2025	May 1, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 26, 2025	Apr 29, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 10, 2025	SEC EDGAR
Current report	8-K	Mar 10, 2025	Mar 10, 2025	SEC EDGAR
Current report	8-K	Jan 27, 2025	Jan 27, 2025	SEC EDGAR
Proxy statement	DEF 14A	Dec 9, 2024	Dec 9, 2024	SEC EDGAR
Current report	8-K	Nov 19, 2024	Nov 20, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 14, 2024	SEC EDGAR
Current report	8-K	Nov 14, 2024	Nov 14, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Aug 8, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Jun 11, 2024	Jun 14, 2024	SEC EDGAR
Current report	8-K	Jun 11, 2024	Jun 13, 2024	SEC EDGAR
Current report	8-K	May 14, 2024	May 14, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 9, 2024	SEC EDGAR
Current report	8-K	May 9, 2024	May 9, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Lineage Cell Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 3-for-1 split on Oct 31, 1997
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LCTX.

Compare: LCTX vs CRBU · LCTX vs ISCO · LCTX vs OCGN · LCTX vs FATE · LCTX vs ZEOX

Revenue growth0.2% · median 1.6%

Operating margin-280.3% · median -599.8%

Net margin16.2% · median -570.3%

Company	Revenue	Growth
LCTX	$10.84M	+0.2%
ISCO	$9.51M	+3.4%
CRBU	$9.44M	+1.6%
ZEOX	$6.99M	–
FATE	$4.75M	-33.4%
OCGN	–	–

Company

Next earnings (est.): Mar 4, 2027, during market hours
Exchange: NYSE
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 77
Held by institutions: 46.1%
Auditor: Baker Tilly US, LLP
SEC CIK: 876343

Advertisement
300 × 250

See a number that looks wrong?